These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23952551)

  • 21. Design of antisense oligonucleotides stabilized by locked nucleic acids.
    Kurreck J; Wyszko E; Gillen C; Erdmann VA
    Nucleic Acids Res; 2002 May; 30(9):1911-8. PubMed ID: 11972327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
    Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides.
    Uemura Y; Kobayashi K
    Drug Deliv; 2019 Dec; 26(1):803-811. PubMed ID: 31385541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stepwise synthesis of oligonucleotide-peptide conjugates containing guanidinium and lipophilic groups in their 3'-termini.
    Grijalvo S; Terrazas M; Aviñó A; Eritja R
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2144-7. PubMed ID: 20206515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.
    Stein CA; Hansen JB; Lai J; Wu S; Voskresenskiy A; Høg A; Worm J; Hedtjärn M; Souleimanian N; Miller P; Soifer HS; Castanotto D; Benimetskaya L; Ørum H; Koch T
    Nucleic Acids Res; 2010 Jan; 38(1):e3. PubMed ID: 19854938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
    Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
    Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
    Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
    Jaschinski F; Korhonen H; Janicot M
    Methods Mol Biol; 2015; 1317():137-51. PubMed ID: 26072406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical modification study of antisense gapmers.
    Stanton R; Sciabola S; Salatto C; Weng Y; Moshinsky D; Little J; Walters E; Kreeger J; DiMattia D; Chen T; Clark T; Liu M; Qian J; Roy M; Dullea R
    Nucleic Acid Ther; 2012 Oct; 22(5):344-59. PubMed ID: 22852836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo properties of therapeutic oligonucleotides containing non-chiral 3' and 5' thiophosphate linkages.
    Duschmalé J; Hansen HF; Duschmalé M; Koller E; Albaek N; Møller MR; Jensen K; Koch T; Wengel J; Bleicher K
    Nucleic Acids Res; 2020 Jan; 48(1):63-74. PubMed ID: 31754711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Free-radical ring closure to conformationally locked α-L-carba-LNAs and synthesis of their oligos: nuclease stability, target RNA specificity, and elicitation of RNase H.
    Li Q; Yuan F; Zhou C; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2010 Sep; 75(18):6122-40. PubMed ID: 20738147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes.
    Hanecak R; Brown-Driver V; Fox MC; Azad RF; Furusako S; Nozaki C; Ford C; Sasmor H; Anderson KP
    J Virol; 1996 Aug; 70(8):5203-12. PubMed ID: 8764029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide Drugs.
    Sewing S; Boess F; Moisan A; Bertinetti-Lapatki C; Minz T; Hedtjaern M; Tessier Y; Schuler F; Singer T; Roth AB
    PLoS One; 2016; 11(7):e0159431. PubMed ID: 27442522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutagenesis by an antisense oligonucleotide and its degradation product.
    Reshat R; Priestley CC; Gooderham NJ
    Toxicol Sci; 2012 Dec; 130(2):319-27. PubMed ID: 22872057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis.
    Vickers TA; Koo S; Bennett CF; Crooke ST; Dean NM; Baker BF
    J Biol Chem; 2003 Feb; 278(9):7108-18. PubMed ID: 12500975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense inhibition of human telomerase by phosphorothioate oligonucleotide-peptide conjugates.
    Diala I; Murao S; Fujii M
    Nucleic Acids Symp Ser (Oxf); 2008; (52):679-80. PubMed ID: 18776562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracerebroventricular Administration of a 2'-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain.
    Toonen LJA; Casaca-Carreira J; Pellisé-Tintoré M; Mei H; Temel Y; Jahanshahi A; van Roon-Mom WMC
    Nucleic Acid Ther; 2018 Apr; 28(2):63-73. PubMed ID: 29565739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.